###### Key messages

What is already known about this subject?
=========================================

-   Pyromellitic dianhydride (PMDA) is one of several highly reactive acid anhydrides.

-   Exposure to acid anhydrides is known to cause skin irritation, mucous reactions and asthma.

What are the new findings?
==========================

-   We report three cases with persistent asthmatic symptoms associated with PMDA exposure. Specific inhalation challenge (SIC) suggests PMDA as an asthmogen in all three cases.

-   SIC is considered the reference method for diagnosing asthma caused by low-molecular-weight substances.

How might this impact on policy or clinical practice in the foreseeable future?
===============================================================================

-   Clinicians diagnosing and treating patients with asthma should be aware of possible work exposure to PMDA. The present cases demonstrate the importance of considering asthma after work as possible delayed work-related asthma.

-   SIC may be useful in confirming causal factors and improving the work environment associated with work-related asthma.

Introduction {#s1}
============

Pyromellitic dianhydride (PMDA) is one of several highly reactive acid anhydrides and used extensively in the production of thermoplastics and high-performance coatings.[@R1] Anhydrides including PMDA are respiratory irritants and immediate-type sensitisers.[@R3] Some anhydrides have been associated with occupational asthma.[@R1] PMDA has also been related to occupational asthma.[@R1] This short report presents three cases where asthma due to PMDA exposure is suggested.

Three workers in a plastic foil manufacturing plant were referred to the Department of Occupational Medicine due to work-related respiratory symptoms. Case A was a 52-year-old ex-smoking male maintenance worker with no previous respiratory symptoms. He had worked for 16 years at the plant. Case B was a 46-year-old non-smoking male operator, working for 4 years with control and monitoring of the extrusion process. He had no previous respiratory symptoms. Case C was a 46-year-old non-smoking male electrician, who had atopic dermatitis and hay fever as a child. He was employed for 24 years.

PMDA had been used at the plant since 2008, to increase the viscosity of plastic food packaging products used in the food industry. Initially, PMDA powder was poured directly in a funnel from 10 kg bags. After a few years, the PMDA bags were opened and added in industrial glove boxes to reduce dust exposure.

In 2014, the company introduced a new larger extruder, where PMDA was added in a semi-open dosing system several metres above the main working area. In the spring of 2015, local exhaust ventilation in the new extruder was closed for repairs. Three employees developed respiratory symptoms within a few months after the new extruder was introduced, particularly when changing filters and during reparations. Respiratory protective equipment was occasionally used during these work processes.

Methods {#s2}
=======

Initial risk identification was performed during workplace visits. Clinical histories focused on individual and occupational risk factors. Serial peak expiratory flow measurements were registered during work and weekends. Medical examinations included chest X-ray and spirometry using an EasyOne Spirometer (ndd Medical Technologies, Andover, Massachusetts, USA). Methacholine Challenge Test was performed according to standardised procedures, delivered from a nebuliser (Jaeger APS-system) by breath-activated dosimeter method in increasing dosages.[@R9] The response to methacholine is measured as the provocation dose that results in a 20% fall in forced expiratory flow in 1 s (FEV~1~) compared with baseline FEV~1~ (PD~20~ methacholine)

Specific immunoglobulin (Ig) E to common aeroallergens and available anhydrides were measured using kits from ThermoFisher.

Specific inhalation challenge (SIC) {#s2a}
-----------------------------------

SIC was performed according to the recommendations of the European Respiratory Society.[@R10] Asthma treatment was carefully reduced before the challenge. SIC was performed in a 7 m^3^ challenge chamber at the outpatient asthma clinic, Odense University Hospital. Temperature, CO~2~, humidity, air exchange and dust particles (DustTrak^R^, TSI, Shoreview, Minnesota, USA) were monitored. Day 1: control challenge with lactose powder. Day 2: active challenge, with pouring 200 g powder (90% lactose and 10% PMDA) back and forth between two trays. Dust levels were between 0.8 and 3.0 mg/m^3^. The active challenge was followed by hospitalisation at the Pulmonary Department. FEV~1~ was registered frequently the first hour and every hour in the additional 10--14 hours thereafter.

Results {#s3}
=======

There were no PMDA air measurements from the workplace. Clinical characteristics of the three cases and their responses to SIC are summarised in [table 1](#T1){ref-type="table"}. Pre-SIC spirometry showed FEV~1~ of 88%, 69% and 106% of predicted values, respectively. Case A had positive specific IgE for three of the five anhydrides. The two other cases had elevated specific IgE for various common aeroallergens. During PMDA challenge, FEV~1~ fell 19%, 15% and 16% after 6 to 12 hours (see [figure 1](#F1){ref-type="fig"}). After 21 hours, FEV~1~ fell by 24% in case B. Termination of PMDA exposure at the plastic foil manufacturing plant resulted in symptoms reduction and in two cases significant improvement in lung function.

###### 

Clinical characteristics and response to SIC

  --------------------------------------------------------------------------------------------------------------------
  Case                                                      A                  B                  C
  --------------------------------------------------------- ------------------ ------------------ --------------------
  Total IgE, kU/L                                           24                 383                664

  Eosinophils, 10^9^/L                                      0.07               0.25               0.16

  Specific IgE, anhydrides                                  Positive \*        Negative           Negative

  Specific IgE, aeroallergens                               Negative           Positive†          Positive‡

  Baseline FEV~1~, L, (% of predicted values), FEV~1~/FVC   3.31 (88%), 0.52   2.41 (69%), 0.74   3.90 (106 %), 0.75

  Peakflow diurnal variability                              20%                16%                Not tested

  Methacholine Challenge Test (PD~20~), µg§                 268                Negative           261

  Maximum fall in FEV~1~/hours from challenge start         19%/4              16%/12\            17%/9
                                                                               24%/24             

  Respiratory symptoms during SIC                           Lower              Lower              Lower
  --------------------------------------------------------------------------------------------------------------------

\*Phthalic anhydride, hexahydrophthalic anhydride, methyltetrahydrophtalic anhydride, positive \>0.1 kU/L.

†*Phleum pratensa*, *Dermatophagoides farinae*, *Dermatophagoides pteronyssinus*, positive \>0.35 kU/L.

‡*Phleum pratensa, Betula verrucosa, Artemisia vulgaris, Cladosporium herbarium*, positive  \> 0.35 kU/ L.

§Dose of metacholine that results in a 20 % fall in FEV~1~, positive  \< 400  µg.

FEV~1~, forced expiratory flow in 1 s; IgE, immunoglobulin E; SIC, specific inhalation challenge.

![Change of FEV~1~ in per cent of baseline values during control and PMDA challenge. FEV~1~, forced expiratory flow in 1 s; PMDA, pyromellitic dianhydride.](oemed-2018-105295f01){#F1}

Discussion {#s4}
==========

The present results suggest that PMDA exposure may cause occupational asthma. Various anhydrides have been associated with asthma.[@R1] PMDA has also been linked to rhinitis, haemorrhagic rhinitis and bronchial hyper-responsiveness.[@R3] A limited number of PMDA-related asthma symptoms have been described. A Japanese group reported two possible cases of occupational asthma caused by PMDA.[@R7] A study with workplace challenges demonstrated asthma in one worker after mixing epoxy and PMDA. It was unknown which component was asthmogentic.[@R6] Two studies using airway resistance identified four cases of PMDA-related asthma.[@R5] The more common fall in FEV~1~ was not used in these studies.

The mechanisms of anhydride-related asthma are not well understood.[@R12] Some individuals with asthma caused by anhydrides show specific IgE antibodies to anhydride--human serum albumin conjugates suggesting IgE mediation.[@R8] Cross-reactivity among anhydrides has been shown.[@R8] No commercial kits analysing specific IgE to PMDA are available. Only one of the three cases had positive specific IgE to the available anhydrides suggesting possible sensitisation. Thus, cross-reactivity with other anhydrides was not useful in these cases. During SIC, the three patients developed lower respiratory symptoms and delayed fall in FEV~1~ suggesting sensitisation.

Anhydrides are also highly irritative.[@R2] The absence of upper respiratory symptoms during SIC argues against an irritant reaction. Furthermore, the exposure levels during SIC were below the occupational exposure limit value for anhydrides in Denmark of 0.4 mg/m^3^ (Maleic anhydride). Thus, an irritative response is less likely. Finally, the delayed asthma resulted from the challenges, further suggest an immunological response.

Due to these results the company expanded the use of respirators and improved ventilation. Finally, the use of PMDA was completely eliminated at the plant. Asthma symptoms were reduced in all three cases after PMDA was eliminated. Two had marked improvement with normalisation of lung function. Lung function was not improved in case B, suggesting that PMDA-associated asthma may be persistent.

SIC is useful in diagnosing occupational asthma due to LMW agents. LMW-associated asthma is often delayed[@R1] and can be identified by SIC. Thus, symptoms after work may be work-related. Correctly diagnosing work-related asthma can be very useful in improving work environments.
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